Overview

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
This study will compare the relative bioavailability of 500 mg Divalproex Sodium Delayed-Release Tablets with that of 500 mg Depakote® Tablets following a single oral dose (1 x 500 mg tablets) in healthy subjects under non-fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Valproic Acid